Business Context and Reporting Period
This Form 8-K was filed by Altimmune, Inc. on July 13, 2020. The filing serves as a Regulation FD disclosure and reports on other events regarding the company's intranasal COVID-19 vaccine candidate, AdCOVID.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development milestones and preclinical study results.
Material Changes and Developments
On July 13, 2020, Altimmune announced positive preclinical data for AdCOVID, developed in collaboration with the University of Alabama at Birmingham (UAB). Key findings include:
- Systemic Immunity: A single intranasal dose achieved serum IgG antibody concentrations greater than 800 micrograms per milliliter 14 days post-administration.
- Neutralization: Serum viral neutralization titers reached 1:320 by Day 28, which is two times higher than the FDA recommendation for investigational convalescent plasma.
- Mucosal Immunity: A single dose stimulated a 29-fold induction of mucosal IgA in bronchoalveolar fluid, a level associated with protection from disease in other mucosal vaccines.
- Cellular Response: Rapid recruitment of immune cells (CD8+, CD4+, dendritic, NK cells) was observed in the respiratory tract, with germinal center and memory B cells observed in lymph nodes and the spleen.
Guidance, Outlook, and Risks
Outlook and Plans:
- The company plans to begin manufacturing AdCOVID and advance the candidate to a Phase 1 safety and immunogenicity study in the fourth quarter of 2020.
- An Investigational New Drug (IND) application is expected to be submitted to the FDA later in 2020.
- AdCOVID is designed for needle-free intranasal administration and is expected to have room temperature stability, potentially eliminating the need for cold-chain logistics.
Risks and Contingencies:
- Forward-looking statements are subject to risks including potential delays in regulatory review, manufacturing, and supply chain interruptions due to the COVID-19 pandemic.
- There is no guarantee of securing regulatory approval for the AdCOVID IND or manufacturing approval from the SARS-CoV-2 cell licensor.
- Preclinical data does not guarantee human safety or efficacy; adverse effects in humans remain a possibility.
Investor Verification Checklist
- Verify the timeline for the submission of the AdCOVID IND application to the FDA.
- Confirm the company's ability to secure manufacturing approval from its SARS-CoV-2 cell licensor.
- Monitor the initiation date of the Phase 1 clinical trial scheduled for Q4 2020.
- Review upcoming data on antigen-specific T cell responses expected in the coming weeks.
- Assess the company's cash runway and capital requirements to fund manufacturing and clinical trials, as this filing does not disclose current liquidity.